Evaluation of Pyrrolizidine Alkaloid-induced Genotoxicity Using Metabolically Competent TK6 Cell Lines
Overview
Toxicology
Authors
Affiliations
Pyrrolizidine alkaloid (PA)-containing plants are among the most common poisonous plants affecting humans, livestock, and wildlife worldwide. A large number of PAs are known to induce genetic damage after metabolic activation. In the present study, using a battery of fourteen newly developed TK6 cell lines, each expressing a single human cytochrome P450 (CYP1A1, 1A2, 1B1, 2A6, 2B6, 2C8, 2C18, 2C9, 2C19, 2D6, 2E1, 3A4, 3A5, and 3A7), we identified specific CYPs responsible for bioactivating three PAs - lasiocarpine, riddelliine, and senkirkine. Among the fourteen cell lines, cells expressing CYP3A4 showed significant increases in PA-induced cytotoxicity, evidenced by decreased ATP production and cell viability, and increased caspase 3/7 activities. LC-MS/MS analysis revealed the formation of 1-hydroxymethyl-7-hydroxy-6,7-dihydropyrrolizine (DHP), the main reactive metabolite of PAs, in CYP3A4-expressing TK6 cells. DHP was also detected in CYP3A5- and 3A7-expressing cells after PA exposure, but to a much lesser extent. Subsequently, using a high-throughput micronucleus assay, we demonstrated that PAs induced concentration-dependent increases in micronuclei and G2/M phase cell cycle arrest in three CYP3A variant-expressing TK6 cell lines. Using Western blotting, we observed that PA-induced apoptosis, cell cycle changes, and DNA damage were primarily mediated by CYP3A4. Benchmark dose (BMD) modeling demonstrated that lasiocarpine, of the three PAs, was the most potent inducer of micronuclei, with a BMD of 0.036 μM. These results indicate that our TK6 cell system holds promise for genotoxicity screening of compounds requiring metabolic activation, identifying specific CYPs involved in bioactivation, and discriminating the genotoxic compounds that have different chemical structures.
Evaluation of weak genotoxicity of hydroxychloroquine in human TK6 cells.
Li X, Le Y, Li Y, Chen S, Guo L, Fu X Toxicol Lett. 2024; 393:84-95.
PMID: 38311193 PMC: 11369915. DOI: 10.1016/j.toxlet.2024.01.012.
Li X, Le Y, Seo J, Guo X, Li Y, Chen S Regul Toxicol Pharmacol. 2023; 141:105410.
PMID: 37210026 PMC: 11393638. DOI: 10.1016/j.yrtph.2023.105410.
The expression of Phase II drug-metabolizing enzymes in human B-lymphoblastoid TK6 cells.
Li X, Li Y, Ning K, Chen S, Guo L, Bonzo J J Environ Sci Health C Toxicol Carcinog. 2022; 40(1):106-118.
PMID: 35895929 PMC: 9346962. DOI: 10.1080/26896583.2022.2044242.
Li X, He X, Le Y, Guo X, Bryant M, Atrakchi A Arch Toxicol. 2022; 96(11):3077-3089.
PMID: 35882637 DOI: 10.1007/s00204-022-03347-6.
In vitro effects of cannabidiol and its main metabolites in mouse and human Sertoli cells.
Li Y, Wu Q, Li X, Von Tungeln L, Beland F, Petibone D Food Chem Toxicol. 2021; 159:112722.
PMID: 34871667 PMC: 10123765. DOI: 10.1016/j.fct.2021.112722.